Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemborexant in Insomnia Disorder (SUNRISE 2)
NCT02952820Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2016
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial of lemborexant in insomnia disorder (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Subjective Sleep Onset Latency at Month 6. Started Nov 2016; status: completed.
02
Drugs
lemborexant
03
Conditions
insomnia disorder
Beyond the preview
Go deeper on NCT02952820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02952820.